keyword
MENU ▼
Read by QxMD icon Read
search

Uro-oncology

keyword
https://www.readbyqxmd.com/read/29767316/-ceus-diagnosis-of-solid-renal-tumors
#1
REVIEW
K Stock, H Kübler, T Maurer, J Slotta-Huspenina, K Holzapfel
CLINICAL ISSUE: Renal lesions are detected earlier, often as a result of ultrasound examinations. However, the imaging-based differential diagnosis of different tumour entities remains challenging STANDARD RADIOLOGICAL METHODS: All renal tumours >1 cm should be evaluated for malignancy by computed tomography (CT) or magnetic resonance imaging (MRI). If an angiomyolipoma diagnosis cannot be established with imaging, further diagnostics are appropriate or if malignant progression is suspected, then multidisciplinary discussion for TNM-staging based uro-oncologic therapy is usual...
May 16, 2018: Der Radiologe
https://www.readbyqxmd.com/read/29749774/bladder-cancer-overview-and-disease-management-part-1-non-muscle-invasive-bladder-cancer
#2
Beverley Anderson
Part 1 of this two-part article provides an overview of bladder cancer and discusses its management. Since publication of a previous article entitled 'Understanding the role of smoking in the aetiology of bladder cancer' ( Anderson, 2009 ), the author has received many requests for an update. This article provides an overview of bladder cancer and its current management practices, underlining the continued role of smoking as the predominant risk factor in the disease's development. The management of bladder cancer is governed by specific guidelines...
May 10, 2018: British Journal of Nursing: BJN
https://www.readbyqxmd.com/read/29720406/contemporary-prostate-biopsy-reporting-insights-from-a-survey-of-clinicians-use-of-pathology-data
#3
Murali Varma, Krishna Narahari, Malcolm Mason, Jon D Oxley, Daniel M Berney
AIM: To determine how clinicians use data in contemporary prostate biopsy reports. METHODS: A survey was circulated to members of the British Association of Urological Surgeons and the British Uro-oncology Group. RESULTS: Responses were received from 114 respondents (88 urologists, 26 oncologists). Ninety-seven (94%) use the number of positive cores from each side and 43 (42%) use the % number of positive cores. When determining the number and percentage of positive cores, 72 (71%) would not differentiate between targeted and non-targeted samples...
May 2, 2018: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29691592/-minimally-invasive-vs-open-partial-nephrectomy-perioperative-success-and-complication-rates
#4
A Boy, J Hein, M Bollow, D Lazica, A Roosen, B Ubrig
BACKGROUND: Solid renal masses are increasingly treated with nephron-sparing surgery. As in other uro-oncological surgical techniques, minimally invasive and robotic-assisted techniques are becoming increasingly popular. OBJECTIVES: The perioperative results from minimally invasive nephron-sparing surgery versus open surgery were retrospectively compared. MATERIALS AND METHODS: In our single center retrospective study, all patients who underwent nephron-sparing tumor excision between 2006 and 2016 were divided into two groups (group O = open approach and group M = minimally invasive approach)...
April 24, 2018: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/29589154/identification-of-curable-high-risk-prostate-cancer-using-radical-prostatectomy-alone-who-are-the-good-candidates-for-undergoing-radical-prostatectomy-among-patients-with-high-risk-prostate-cancer
#5
Kazuhiro Nagao, Hideyasu Matsuyama, Hiroaki Matsumoto, Takahito Nasu, Mitsutaka Yamamoto, Yoriaki Kamiryo, Yoshikazu Baba, Akinobu Suga, Yasuhide Tei, Satoru Yoshihiro, Akihiko Aoki, Tomoyuki Shimabukuro, Keiji Joko, Shigeru Sakano, Kimio Takai, Shiro Yamaguchi, Jumpei Akao, Seiji Kitahara
BACKGROUND: Currently, there is no consensus regarding which patients with high-risk prostate cancer (PCa) would benefit the most by radical prostatectomy (RP). We aimed to identify patients with high-risk PCa who are treatable by RP alone. METHODS: We retrospectively reviewed data on 315 patients with D'Amico high-risk PCa who were treated using RP without neoadjuvant or adjuvant therapy at the institutions of the Yamaguchi Uro-Oncology Group between 2009 and 2013...
March 27, 2018: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29556486/differences-in-clinical-outcome-between-docetaxel-and-abiraterone-acetate-as-the-first-line-treatment-in-chemo-na%C3%A3-ve-metastatic-castration-resistant-prostate-cancer-patients-with-or-without-the-ineligible-clinical-factors-of-the-cou-aa-302-study
#6
Darren M C Poon, Kuen Chan, Siu H Lee, Tim W Chan, Henry Sze, Eric K C Lee, Daisy Lam, Michelle F T Chan
Background: This study aimed to compare the efficacy of abiraterone acetate (AA) versus docetaxel (T) as first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer (mCRPC) patients with or without the ineligible factors of the COU-AA-302 study (presence of visceral metastases, symptomatic disease, and/or Eastern Cooperative Oncology Group performance status ≥ 2). Materials and methods: The clinical records of chemo-naïve mCRPC patients who received AA in six public oncology centers or T in two of these centers between 2003 and 2014 were reviewed...
March 2018: Prostate International
https://www.readbyqxmd.com/read/29508029/-oncological-emergencies-in-chemotherapy-febrile-neutropenia-tumor-lysis-syndrome-and-extravasation
#7
REVIEW
G von Amsberg
BACKGROUND: Uro-oncological emergencies can be caused by the tumor, treatment complications, or non-oncological diseases. This review focuses on chemotherapy-associated emergencies, especially febrile neutropenia (FN), tumor lysis syndrome (TLS), and extravasations. AIM: The goal is to provide an overview on the most relevant chemotherapy-associated emergencies and treatment methods. MATERIALS AND METHODS: The ESMO (European Society of Medical Oncology), EORTC (European Organization for Research and Treatment of Cancer), and S3 guidelines were used for the preparation of this review and a PubMed search was performed for "febrile neutropenia", "extravasation", and "tumor lysis syndrome"...
May 2018: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/29461273/relationship-of-surgeon-hospital-volume-with-outcomes-in-uro-oncology-surgery
#8
Pietro Grande, Riccardo Campi, Morgan Rouprêt
PURPOSE OF REVIEW: Hospital and surgical volumes, as well as complications, are considered to influence intra and postoperative results in most surgical operations. This trend is also seen in uro-oncologic surgery. The objective of this review is to critically analyze the most recent literature to give a comprehensive overview on whether surgical and hospital volumes have an impact, and whether regionalization of the procedure should be advised. RECENT FINDINGS: Uro-oncologic surgery has recently become more regionalized, and data coming from different population-based analyses appear to support this trend...
May 2018: Current Opinion in Urology
https://www.readbyqxmd.com/read/29390215/das-bewegt-die-urologie-%C3%A2-aktuelles-von-den-kongressen-2017
#9
Hendrik Heers, Martin Boegemann, Axel Hegele
In 2017, many new and promising therapeutic innovations entered uro-oncology. Immunotherapy was highly topical and was intensively discussed at the annual meetings. This review summarises the news, together with future developments in the diagnosis and treatment of prostate, bladder and kidney cancer. Within the last year, there have been major developments in the treatment of hormone sensitive metastastic prostate cancer, metastatic transitional cell carcinoma and metastastic renal cell cancer. Many new drugs will be added to our therapeutic arsenal during the upcoming months...
February 2018: Aktuelle Urologie
https://www.readbyqxmd.com/read/29372352/three-dimensional-models-in-uro-oncology-a-future-built-with-additive-fabrication
#10
Todd G Manning, Jonathan S O'Brien, Daniel Christidis, Marlon Perera, Jasamine Coles-Black, Jason Chuen, Damien M Bolton, Nathan Lawrentschuk
PURPOSE: Three-dimensional (3D) printing was invented in 1983 but has only just begun to influence medicine and surgery. Conversion of digital images into physical models demonstrates promise to revolutionize multiple domains of surgery. In the field of uro-oncology, researchers and clinicians have recognized the potential of this technology and are working towards making it an integral part of urological practice. We review current literature regarding 3D printing and other 3D technology in the field of urology...
April 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29348903/the-systemic-inflammation-based-glasgow-prognostic-score-as-a-powerful-prognostic-factor-in-patients-with-upper-tract-urothelial-carcinoma
#11
Teruo Inamoto, Hideyasu Matsuyama, Shigeru Sakano, Naokazu Ibuki, Kiyoshi Takahara, Kazumasa Komura, Tomoaki Takai, Takuya Tsujino, Yuki Yoshikawa, Koichiro Minami, Kazuhiro Nagao, Ryo Inoue, Haruhito Azuma
Introduction and Objective: The combination of C-reactive protein and albumin, the Glasgow Prognostic Score (GPS), had independent prognostic value in patients with varying cancers, except for upper tract urothelial carcinoma (UTUC). The aim of this study was to describe the relationship between GPS and survival in patients with UTUC after adjustment for other prognostic factors. Materials and Methods: We queried 2 UTUC databases. Retrospective clinical series on patients with localized UTUC managed by nephroureterectomy with bladder cuff, for whom data from the Yamaguchi Uro-Oncology Group and Osaka Medical College registry, including age, presence of bladder cancer, pT stage, lymphovascular invasion, C-reactive protein (CRP) and albumin, were analyzed...
December 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29281857/outcomes-of-subsequent-non-muscle-invasive-bladder-cancer-treated-with-intravesical-bacillus-calmette-gu%C3%A3-rin-after-radical-nephroureterectomy-for-upper-urinary-tract-urothelial-carcinoma
#12
Makito Miyake, Yoshihiro Tatsumi, Hiroaki Matsumoto, Kazuhiro Nagao, Hideyasu Matsuyama, Teruo Inamoto, Haruhito Azuma, Hiroaki Yasumoto, Hiroaki Shiina, Kiyohide Fujimoto
OBJECTIVES: To describe the clinicopathological characteristics and prognosis of subsequent non-muscle-invasive bladder cancer (NMIBC) after radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC), and particularly its response to intravesical Bacillus Calmette-Guérin (BCG). PATIENTS AND METHODS: An observational study was conducted in 1463 patients with UTUC who had undergone RNU and in 1555 patients with primary NMIBC. Of the 1463 patients with UTUC, 256 (17%) subsequently developed NMIBC (UTUC-NMIBC group) and were available for the analysis...
May 2018: BJU International
https://www.readbyqxmd.com/read/29250197/antiangiogenic-therapies-in-urogenital-malignancies-fiction-or-fact
#13
REVIEW
Friederike Haidl, David Pfister, Axel Heidenreich, Isabel Heidegger
The use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. However, concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic renal cell cancer. Yet in recent years, several approaches for sequential treatment with angiogenesis inhibitors in other urogenital malignancies apart from renal cell cancer are ongoing. Thus, the present review article aims to provide an overview about clinical studies with antiangiogenic agents in prostate-, bladder-, testicular-, as well as penile cancer patients...
2017: Memo
https://www.readbyqxmd.com/read/29241310/indocyanine-green-fluorescence-guided-sentinel-lymph-node-identification-in-urologic-cancers-a-systematic-review-and-meta-analysis
#14
Fouad Aoun, Simone Albisinni, Marc Zanaty, Toufic Hassan, Gunter Janetschek, Roland van Velthoven
INTRODUCTION: To date, bilateral pelvic lymph node dissection (PLND) represents the most accurate and reliable staging procedure for the detection of lymph node invasion in prostate cancer and bladder cancer. However, the procedure is not devoid of complications. In this field, Indocyanine green fluorescence-guided sentinel lymph node (SLN) identification is an emerging and promising technique, as accurate staging of urologic cancer could be enhanced by a thorough evaluation of the sentinel lymph nodes...
December 14, 2017: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/29211320/consensus-statements-on-the-management-of-metastatic-prostate-cancer-from-the-hong-kong-urological-association-and-hong-kong-society-of-uro-oncology
#15
REVIEW
Darren Ming-Chun Poon, Chi-Kwok Chan, Tim-Wai Chan, Foon-Yiu Cheung, Philip Wai-Kay Kwong, Eric Ka-Chai Lee, Angus Kwong-Chuen Leung, Simon Yiu-Lam Leung, Wai-Kit Ma, Hing-Shing So, Po-Chor Tam, Lap-Yin Ho
To establish a set of consensus statements to facilitate physician management strategies for patients with metastatic prostate cancer (mPCa) in Hong Kong. A local expert consensus was organized jointly by the two main professional organizations representing prostate cancer specialists in Hong Kong. A total of 12 experts were included in the consensus panel. Six of the most crucial and relevant areas of debate regarding the management of mPCa were identified. With the use of a modified Delphi method, several panel meetings were held for the members to discuss their clinical experience and the published literature relevant to the areas of debate...
May 2018: BJU International
https://www.readbyqxmd.com/read/29196208/eradicate-a-prospective-evaluation-combining-radium-223-dichloride-and-abiraterone-acetate-plus-prednisone-in-patients-with-castration-resistant-prostate-cancer
#16
Neal D Shore, Ronald F Tutrone, Neil F Mariados, Luke T Nordquist, Bryan A Mehlhaff, Karyn J Steere, Stacey S Harrelson
BACKGROUND: Multiple castration-resistant prostate cancer (CRPC) therapies are approved by the United States Food and Drug Administration. Radium-223 dichloride (Ra-223) with abiraterone acetate plus prednisone have different mechanisms of action and distinct off-target side-effect profiles. We prospectively investigated their combined safety, tolerability, and patient-reported outcome measures. PATIENTS AND METHODS: eRADicAte, an investigator-initiated, phase II trial, studied 31 patients with metastatic CRPC, from 5 United States uro-oncology research sites...
April 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29185631/-myths-and-reality-about-immunonutrition-in-uro-oncology
#17
Yannick Cerantola
Postoperative morbidity remains a nightmare (although vivid), both for the patient and the surgeon. One phantasmagorical idea would be to give the patient a « magic potion » preoperatively aiming at eliminating the risk of postoperative complication. The purpose of the present review is to summarize the current knowledge on the potential benefits of immunonutrition administered to urological cancers patients. After a brief summary on the role of immunity in cancer surveillance and treatment, the rationale about administrating oral nutritional supplements able to modulate the patient's immune system before cystectomy for bladder cancer will be highlighted...
November 29, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29075832/-68-ga-psma-11-ligand-pet-imaging-in-patients-with-biochemical-recurrence-after-radical-prostatectomy-diagnostic-performance-and-impact-on-therapeutic-decision-making
#18
B Grubmüller, P Baltzer, D D'Andrea, S Korn, A R Haug, M Hacker, K H Grubmüller, G M Goldner, W Wadsak, S Pfaff, J Babich, C Seitz, H Fajkovic, M Susani, P Mazal, G Kramer, S F Shariat, Markus Hartenbach
OBJECTIVE: To evaluate the diagnostic performance of [68 Ga]Ga-PSMAHBED-CC conjugate 11 positron emission tomography (PSMA-PET) in the early detection of metastases in patients with biochemical recurrence (BCR) after radical prostatectomy (RP) for clinically non-metastatic prostate cancer, to compare it to CT/MRI alone and to assess its impact on further therapeutic decisions. MATERIAL AND METHODS: We retrospectively assessed 117 consecutive hormone-naïve BCR patients who had 68 Ga-PSMA 11 PET/CT (n = 46) or PET/MRI (n = 71) between May 2014 and January 2017...
February 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29037861/biological-behavior-and-long-term-outcomes-of-carcinoma-in-situ-in-upper-urinary-tract-managed-by-radical-nephroureterectomy
#19
Teruo Inamoto, Hideyasu Matsuyama, Naokazu Ibuki, Kazumasa Komura, Kiyoshi Takahara, Kiyohide Fujimoto, Hiroaki Shiina, Shigeru Sakano, Kazuhiro Nagao, Makito Miyake, Yoshihiro Tatsumi, Hiroaki Yasumoto, Haruhito Azuma
PURPOSE: In patients with urothelial carcinoma CIS (carcinoma in situ) generally has a poor prognosis. However, to our knowledge the outcomes of pure/primary CIS and the behavior of CIS concomitant with pTa-pT4 upper tract urothelial carcinoma managed by nephroureterectomy have not been previously specified. We explored the biological and prognostic features of concomitant CIS compared with those of pure/primary CIS. MATERIALS AND METHODS: We queried a multicenter upper tract urothelial carcinoma database...
April 2018: Journal of Urology
https://www.readbyqxmd.com/read/28887095/psychological-distress-in-patients-undergoing-surgery-for-urological-cancer-a-single-centre-cross-sectional-study
#20
Antonio Luigi Pastore, Ana Mir, Serena Maruccia, Giovanni Palleschi, Antonio Carbone, Cristina Lopez, Nuria Camps, Joan Palou
PURPOSE: Interest in the disease-specific psychological well-being of patients with cancer has increased, and it has been estimated that less than half of all patients with cancer are properly identified and subsequently treated for anxiety or depression. The aim of this study is to evaluate psychological distress in uro-oncological patients undergoing different surgeries: radical cystectomy, radical prostatectomy, radical nephrectomy, or transurethral resection (TUR) before the surgery...
December 2017: Urologic Oncology
keyword
keyword
78801
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"